Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer

Video

This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer.

In this video, Prudence A. Francis, MD, of the Peter MacCallum Cancer Centre in Melbourne, reviews trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal estrogen receptor (ER)-positive breast cancer.

Francis gave a presentation on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Recent Videos
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content